Tenet Healthcare director Roy Blunt sells $293,000 in shares By Investing.com
Roy Blunt, a director at Tenet Healthcare Corp. (NYSE:THC), recently sold 1,000 shares of the company's common stock for $293,000. This transaction occurred on November 11, 2026, with shares priced at $293.00 each, following a strong year-to-date return of 44% for the stock. Despite the sale, Tenet Healthcare recently reported stronger-than-expected Q3 2026 results, leading to raised outlooks and positive analyst ratings from Mizuho and Guggenheim.
Form 144 TENET HEALTHCARE CORP For: 12 November By Investing.com
This article reports on a Form 144 filing by Tenet Healthcare Corp (THC) for November 12. Form 144 is a notice of the intent to sell restricted securities. The article includes the stock symbol THC and its current performance of -2.09%.
Form 144 TENET HEALTHCARE CORP For: 12 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Tenet Healthcare Corp (THC) on November 12, 2026. Form 144 indicates an intent to sell restricted securities, providing transparency regarding potential insider transactions. The brief report highlights the company's stock symbol and a slight dip in its stock performance.
Director Roy D. Blunt proposes selling 1,000 Tenet Healthcare (THC) shares worth $293,000.
Tenet Healthcare director Roy D. Blunt has filed a Form 144 proposing to sell 1,000 common shares of THC, valued at $293,000, with an approximate sale date of November 11, 2026. The shares were originally acquired through restricted-stock vesting on August 9, 2026, as compensation. Fidelity Brokerage Services LLC is named as the broker for this transaction.
Tenet Healthcare (THC) Is Back In Focus, What Is The Market Weighing?
Tenet Healthcare (THC) has garnered market attention following its recent earnings report, which highlighted increased quarterly and nine-month sales and net income, alongside an upward revision of its full-year earnings outlook. The company's share price has seen a substantial rise of 45.54% year-to-date. Despite this strong performance and raised guidance, the stock trades below analyst targets and some intrinsic value estimates, prompting questions about potential mispricing versus market skepticism regarding execution on growth and cost programs.
Learn Why The Bull Case For Tenet Healthcare Stock Could Change Following Raised 2026 Guidance
Tenet Healthcare reported strong Q3 2026 results with US$5,631 million in sales and US$1,000 million in net income, leading to raised full-year 2026 guidance for net operating revenues (US$22,050 million to US$22,450 million) and diluted EPS (US$35.82 to US$37.08). This optimistic outlook is driven by performance in high acuity outpatient and behavioral health, which are crucial for the company's ability to fund M&A, technology, and buybacks while managing its leveraged balance sheet.
What Tenet Healthcare Holders Got Right
Tenet Healthcare (NYSE: THC) shareholders who invested at the start of 2026 saw a 42.1% return, including dividends, demonstrating the success of the optimistic view on the company's growth. The company's Q3 2026 results, with net income climbing to US$1.0 billion and net margin increasing to 17.8%, further supported the bullish case driven by aging demographics and outpatient expansion. However, the current share price of US$283 exceeds the calculated Fair Value, suggesting the stock may be ahead of its underlying assumptions.
What Tenet Healthcare Bulls Got Right
Tenet Healthcare's shares have seen a significant 43.6% return year-to-date, including dividends, driven by strong earnings and higher guidance. The bullish case, which centered on aging patients shifting to high-acuity outpatient care via the USPI platform, was validated by the Q3 2026 report showing increased revenue and net income. While the stock now trades above the selected Narrative's estimated fair value, sustained growth in behavioral health and outpatient integration could support its current price.
Tenet Healthcare (THC) Stock Looks Below Fair Value On Current Earnings
Tenet Healthcare (THC) appears undervalued based on its current earnings, trading at a P/E ratio of roughly 7.9x compared to a sector average of 25.8x. Despite a significant multi-year stock run and recent positive earnings sentiment, its valuation remains discounted relative to both industry peers and a tailored benchmark. The article explores bull and bear cases for the stock's future value, emphasizing the importance of aligning its share price with current and projected earnings.
Tenet Healthcare Corporation (THC) Stock Forecasts
Argus has raised its price target for Tenet Healthcare Corporation (THC) to $293.00, citing the company's strong position in healthcare services. As of November 4, 2026, THC's current price is $292.25. Tenet Healthcare operates 47 acute and specialty hospitals and over 500 ambulatory surgery centers across the U.S., predominantly in the South.
Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical stocks trade up, what you need to know
Several healthcare and biotechnology stocks, including Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical, surged after election results confirmed Democratic majorities in the House and Senate. This outcome eased regulatory uncertainty surrounding drug pricing policy, leading Wall Street analysts to project a stronger recovery for the biopharmaceutical sector. The shift in congressional power is seen as creating a more predictable regulatory climate, encouraging investments in pharmaceutical and biotechnology development.
Tenet Healthcare Corporation (THC) Stock Forecasts
Morningstar published an analyst report on Tenet Healthcare Corporation (THC) on November 4, 2026, noting that Democratic Congressional victories in the midterm election boosted medical services shares. Tenet Healthcare is a Dallas-based healthcare services organization operating acute and specialty hospitals, ambulatory surgery centers, and other outpatient facilities primarily in the US South. The report provides a summary of the company's operations and an overview of the analyst.
Barclays maintains Tenet Healthcare at Overweight, raises price target to $297 from $271
Barclays has reiterated its Overweight rating for Tenet Healthcare (THC) and increased its price target to $297 from $271, suggesting an 11.4% upside from its previous close. This action aligns with other recent analyst upgrades, with price targets from various firms ranging between $300 and $342.
Tenet Healthcare Corporation stock hits all-time high at 285.71 USD
Tenet Healthcare Corporation (THC) stock has reached an all-time high of $285.71, reflecting strong performance and investor confidence. The company reported impressive third-quarter 2026 results, surpassing analyst expectations with adjusted EPS of $6.64 and revenue of $5.63 billion, and raised its full-year adjusted EBITDA outlook. Analysts from Mizuho and Guggenheim have maintained positive ratings and price targets, with InvestingPro analysis suggesting the stock remains undervalued.
Health insurers, hospitals rally after sweeping midterm win for Democrats
Shares of Medicaid-focused US health insurers and hospital operators increased after Democrats secured a sweeping midterm election win. Analysts believe the Democratic victory could postpone or prevent the implementation of parts of President Donald Trump’s healthcare bill, which was expected to reduce Medicaid enrollment and limit state healthcare payments, thereby easing pressure on the sector. This outcome may also enhance prospects for extending enhanced subsidies for Affordable Care Act plans.
Keybanc maintains Tenet Healthcare at Overweight, raises price target to $300 from $270
Keybanc has reiterated its "Overweight" rating for Tenet Healthcare (THC) and increased its price target from $270 to $300, signaling an 11.1% hike. This new target implies an 11.6% upside from the stock's closing price on November 2nd. Other analysts have also recently issued "Outperform" or "Buy" ratings with price targets ranging from $304 to $342.
Tenet Healthcare Earnings Call Signals Stronger Growth Ahead
Tenet Healthcare reported a strong third quarter with substantial profit, margin, cash flow, and share repurchase gains. The company delivered $5.6 billion in net operating revenue and raised its 2026 adjusted EBITDA outlook to $5.05 billion-$5.2 billion. Management emphasized its ambulatory growth strategy, debt refinancing, and commitment to returning free cash flow to shareholders, despite acknowledging risks from exchange-related pressure and regulatory uncertainty.
Investors Are Betting a Blue Wave Will Help Hospitals. Don’t Count on It.
Healthcare investors are betting on a "Blue Wave" election outcome to benefit hospital operators, anticipating a reversal of Trump's Medicaid cuts. However, the article cautions against this assumption, reminding investors of past difficulties in rolling back healthcare agendas when an opposition party gained control. The piece suggests that such a reversal might be harder to achieve than markets currently anticipate.
Tenet Healthcare (THC) Stock Price, Chart & Analysis
This article provides a comprehensive analysis of Tenet Healthcare (THC) stock, detailing its current price ($268.89), market capitalization ($21.75B), and listing on the NYSE. It offers insights into the company's financial health, including revenue growth, net margin, debt levels, and a "Belegger score," along with frequently asked questions, key figures, and valuation scenarios for investors.
Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook
Tenet Healthcare Corporation announced strong third-quarter 2026 results, with net income available to common shareholders reaching $1 billion, or $12.41 per diluted share. The company also raised its full-year 2026 financial outlook, with Adjusted EBITDA now expected to be between $5.05 billion and $5.20 billion, and Adjusted Free Cash Flow projected to be between $2.825 billion and $3.125 billion. This outperformance was attributed to robust same-store revenue growth and efficient expense management across its Ambulatory Care and Hospital Operations segments.
Tenet sails past Q3 earnings estimates, boosts 2026 guidance
Tenet Healthcare reported strong third-quarter 2026 results, with net operating revenues reaching $5.63 billion and adjusted earnings per share of $6.64, significantly exceeding analyst estimates. This performance, driven by growth in both its hospital and ambulatory businesses, led the company to raise its 2026 adjusted EBITDA guidance by $195 million and express confidence in continued earnings growth in 2027. Executives highlighted rising hospital activity, expense reductions, and strategic focus on high-acuity patients in the ambulatory segment.
Tenet Healthcare Q3 2026 Earnings Call Transcript
Tenet Healthcare reported strong third-quarter 2026 results with $5.6 billion in net operating revenues and a significant 80% increase in adjusted diluted EPS to $6.64. The company raised its full-year 2026 adjusted EBITDA guidance, driven by robust performance in its USPI segment and hospital operations, along with one-time contract transition benefits. Tenet continues to focus on strategic growth, M&A in USPI, and disciplined expense management, while returning over $1.6 billion to shareholders through share repurchases year-to-date.
Tenet Expects to Grow Underlying Profits in 2027, Despite Policy Headwinds
Tenet Healthcare has undergone a significant turnaround since late 2017, improving governance, divesting underperforming assets, and restructuring operations. The company is expanding high-acuity services in outpatient surgery centers, boosting efficiency, and focusing on service quality. These efforts are expected to lead to growing underlying profits by 2027, with the high-margin ambulatory surgery business offering long-term growth opportunities.
Tenet: Q3 Earnings Snapshot
Tenet Healthcare Corp. (THC) reported strong third-quarter earnings of $1 billion, or $12.41 per share, significantly exceeding Wall Street's expectations. Adjusted earnings were $6.64 per share, surpassing the average analyst estimate of $4.60 per share. The hospital operator also beat revenue forecasts, posting $5.63 billion against an expected $5.47 billion, and provided optimistic full-year earnings and revenue guidance.
Tenet Healthcare (THC) reports earnings tomorrow: what to expect
Tenet Healthcare (THC) is set to report earnings before the market open tomorrow. The company previously exceeded revenue expectations, reporting $5.63 billion, up 6.8% year-on-year, and also beat EPS estimates. For the upcoming quarter, analysts anticipate a 4.3% year-on-year revenue growth, and positive investor sentiment in the healthcare providers & services segment, with Tenet Healthcare's shares up 2% over the last month.
Tenet Healthcare (THC) reports earnings tomorrow: what to expect
Tenet Healthcare (THC) is set to report its earnings before market open this Thursday. Analysts expect a 4.3% year-on-year revenue growth, an improvement from the previous year, despite the company having missed revenue estimates multiple times in the past two years. Investors in the healthcare providers & services segment have shown positive sentiment recently, with Tenet Healthcare's shares up 2% in the last month.
Growth Leads Before Fed, Huge Earnings; Tesla, Nucor, Tenet Healthcare In Focus
Alissa Coram and Ed Carson discuss Tuesday's market performance, highlighting growth leads before the Federal Reserve's meeting and significant earnings reports. The discussion focuses on key stocks to watch, including Tesla, Nucor, and Tenet Healthcare, providing insights into current market action.
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Tenet Healthcare Corporation is expected to report its third-quarter 2026 results on October 29, 2026. The company is projected to beat earnings estimates, with a Zacks Consensus Estimate of $4.60 per share and revenues of $5.47 billion, driven by strong growth in its Ambulatory Care business. Despite a slight decline in total hospital admissions, the Ambulatory Care segment is anticipated to show significant year-over-year increases in net operating revenues and adjusted EBITDA.
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Tenet Healthcare Corporation (THC) is poised to report its third-quarter 2026 earnings, with analysts expecting a significant year-over-year increase in both earnings per share and revenues, driven largely by strong performance in its Ambulatory Care segment. The company has a history of beating earnings estimates, and a positive Earnings ESP combined with a Zacks Rank #3 suggests a likely beat again this quarter. While hospital admissions may see a slight decline, the Ambulatory Care business's growth and facility acquisitions are expected to contribute positively to the results.
Tenet Healthcare Tracking Pixel Class Action Settlement
Tenet Healthcare Corp. has agreed to an $8.5 million settlement in a class action lawsuit regarding its use of "tracking pixels" on its websites and patient portals. Individuals who visited a Tenet Healthcare website or patient portal between January 1, 2017, and September 18, 2023, may be eligible to claim a $16 cash payment or two years of CyEx Privacy Shield Pro. The claim deadline for this settlement is March 15, 2027.
Tenet Healthcare Corporation Estimates – NYSE:THC
This page provides financial estimates for Tenet Healthcare Corporation (NYSE: THC), including reported financial data and analyst estimates across the income statement, balance sheet, cash flow statement, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Tenet Healthcare Corporation Estimates – TRADEGATE:THC1
This page provides financial actuals and analyst estimates for Tenet Healthcare Corporation (THC1) on the Tradegate Exchange. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Tenet Healthcare rated Buy after strong Q2 results and margin growth, with attractive valuation and growth prospects.
Tenet Healthcare received a Buy rating due to strong Q2 financial results, including a significant rise in adjusted EBITDA and EPS, and an upward revision of 2026 guidance. United Surgical Partners International (USPI) is a key growth driver, though volume recovery is crucial for future gains. The company's robust free cash flow supports share buybacks and acquisitions, but investors should monitor hospital margin sustainability and USPI volume trends.
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
Tenet Healthcare (THC) shares closed down 1.17% in the latest trading session, underperforming broader market gains. The company is set to release its earnings on October 29, 2026, with analysts predicting significant growth in EPS and revenue. Investors are monitoring changes to analyst estimates and the stock's valuation, currently holding a Zacks Rank of #3 (Hold).
Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
Tenet Healthcare (THC) has been a highly searched stock on Zacks.com, showing a +3.9% return over the past month, outperforming the S&P 500 and its industry. The article delves into the company's earnings estimate revisions, revenue growth, and valuation, noting a Zacks Rank #3 (Hold) and an "A" grade for value. Investors are encouraged to consider these fundamental factors alongside market buzz.
Zacks cuts Tenet estimate as Tenet Healthcare stock awaits results
Zacks has lowered its 2027 earnings estimate for Tenet Healthcare to USD 5.12 from USD 5.13. This revision, though small, focuses attention on the upcoming third-quarter 2026 results scheduled for October 29. The company had previously raised its adjusted EBITDA guidance, and the market will be watching to see if this can offset potentially softer procedure volumes.
Tenet Healthcare lifts EBITDA outlook. October 29 results test Tenet Healthcare stock
Tenet Healthcare has increased its 2026 adjusted earnings outlook by $295 million at the midpoint, citing a stronger focus on ambulatory care and improved hospital margins. The company's second-quarter revenue grew by 6.8% to $6.04 billion, and adjusted free cash flow guidance also rose. Investors are now awaiting the third-quarter results on October 29, 2026, to assess if this positive momentum continues.
Form PRE 14A Tenet Healthcare Corporation For: 16 October By Investing.com
This article announces the filing of Form PRE 14A by Tenet Healthcare Corporation, dated October 16. The content is a brief notification from Investing.com about this regulatory filing.
Learn Why The Bull Case For Tenet Healthcare Stock Could Change Following Guidance Raise
Tenet Healthcare has raised its 2026 adjusted EBITDA and free cash flow guidance due to stronger performance in ambulatory care and improved hospital margins. This upgrade reinforces the investment thesis centered on the shift towards outpatient surgery centers and higher-margin hospital activities. The article discusses how this guidance change impacts the valuation debate and stresses the importance of assessing execution, payer mix, and policy risks.
THC Maintained by Guggenheim -- Price Target Raised to $307
Guggenheim analyst Jason Cassorla maintained a 'Buy' rating for Tenet Healthcare (THC) and raised its price target to $307 from $283 on October 16, 2026. Despite this positive outlook, GuruFocus indicates that THC is 47.2% overvalued at $275.13 compared to its GF Value™ of $186.89, with significant insider selling observed in recent months. The company has a solid GF Score™ of 74/100, driven by strong momentum and profitability, but its valuation rank is a concern for potential investors.
Guggenheim raises Tenet Healthcare stock price target on momentum
Guggenheim has increased its price target for Tenet Healthcare (NYSE:THC) to $307 from $283, while maintaining a Buy rating, citing strong momentum in its high-acuity and cost efficiency strategies. The firm anticipates solid third-quarter 2026 execution and continued focus on M&A at USPI. Despite some headwinds and elevated crowding of the stock, Guggenheim believes operating momentum and peer multiple expansion clear a path for upside against 2027 consensus.
Guggenheim maintains Buy rating on Tenet Healthcare, $307 price target
Guggenheim has reiterated its Buy rating on Tenet Healthcare (THC) with a price target of $307, indicating an 11.6% upside from its recent closing price. The firm anticipates strong revenue and EBITDA growth for Tenet Healthcare, forecasting $22.220 billion in revenue for 2026 and an 8.1% year-over-year increase in EBITDA. This positive outlook is supported by the company's robust capital deployment strategies and potential for strategic acquisitions and share repurchases.
Tenet Healthcare Corporation (THC) Options Chain - Yahoo Finance
The article provides the options chain for Tenet Healthcare Corporation (THC) on Yahoo Finance. It displays the stock's real-time price, which closed at $267.25 with a decrease of 2.86%. The options chain, specifically for calls and puts, shows no available contracts at the time of publication, indicating a lack of activity or available data for in-the-money options.
Argus raises target to USD 284 for Tenet Healthcare stock
Argus has raised its price target for Tenet Healthcare (THC) to $284 following the company's strong second-quarter 2026 results. The healthcare provider reported $5.60 billion in revenue and adjusted EBITDA of $1.304 billion, with outpatient care and cost control being key drivers of performance. Investors are now looking to the third-quarter results, due on October 29, 2026, to see if Tenet can continue its positive momentum.
Tenet Healthcare Corporation (THC) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive information on Tenet Healthcare Corporation (THC), including its current stock price, historical data, and key financial metrics. It details the company's operations within the diversified healthcare services sector, offering various medical care facilities and services across the United States. The article also presents performance overviews, earnings trends, and analyst insights, indicating a strong performance compared to the S&P 500.
Tenet Healthcare (THC) Draws A Higher Price Target, Is It Fully Priced?
Argus recently raised its price target for Tenet Healthcare (THC) to US$284, drawing attention to the company's valuation. While the stock has seen strong momentum with a 38.77% 90-day return, its current price of US$266.91 suggests it might be slightly overvalued compared to the most followed narrative's fair value of US$260. Despite this, its P/E ratio of 9.6x is significantly lower than peers, potentially indicating either investor concern about debt and earnings or a mispriced opportunity.
US88033GDU13 Bond Yield and Price — BONDSCOM:US88033GDU13
This page provides detailed information on the Tenet Healthcare Corporation 6.75% 15-MAY-2031 bond, identified by ISIN US88033GDU13. It includes key terms such as outstanding amount, face value, coupon rate, and maturity date, along with bond and issuer information. The article also touches upon the company's business segments and offers access to credit ratings and advanced bond data upon signup.
Tenet Healthcare (NYSE:THC): A Decent Value Stock Trading at a Discount
Tenet Healthcare (NYSE:THC) is identified as a decent value stock trading at a discount, fitting a framework that seeks profitability, financial health, and growth. The company scores high in valuation and profitability, with its strong financial metrics suggesting it's not a distressed business. While its debt load presents a risk, management's efforts to reduce debt and shrink share count support the value case, despite slower forecasted growth.
Tenet Healthcare refinances debt: Tenet Healthcare stock sits 8.33 percent below its high
Tenet Healthcare Corporation refinanced $2.00 billion of senior notes due 2034, extending its debt maturity profile and demonstrating balance sheet progress. The company reported a 6.8% revenue increase to $5.63 billion in Q2 2026, despite a slight drop in surgical cases, and its stock is currently 8.33% below its 52-week high. Tenet is set to release its Q3 2026 earnings on October 29, 2026.
$1000 Invested In Tenet Healthcare 15 Years Ago Would Be Worth This Much Today
This article highlights Tenet Healthcare's strong performance over the past 15 years, outperforming the market with an average annual return of 19.49%. A hypothetical $1000 investment in THC stock 15 years ago would now be worth $14,709.18. The piece emphasizes the significant impact of compounded returns on cash growth over time.